Artículos de revistas
Multiple Uses Of Fibrin Sealant For Nervous System Treatment Following Injury And Disease
Registro en:
Journal Of Venomous Animals And Toxins Including Tropical Diseases. Biomed Central Ltd, v. 23, p. , 2017.
1678-9199
WOS:000397661100001
10.1186/s40409-017-0103-1
Autor
Biscola
Natalia Perussi; Cartarozzi
Luciana Politti; Ulian-Benitez
Suzana; Barbizan
Roberta; Castro
Mateus Vidigal; Spejo
Aline Barroso; Ferreira
Rui Seabra
Jr.; Barraviera
Benedito; Rodrigues Oliveira
Alexandre Leite
Institución
Resumen
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Lesions to the nervous system often produce hemorrhage and tissue loss that are difficult, if not impossible, to repair. Therefore, scar formation, inflammation and cavitation take place, expanding the lesion epicenter. This significantly worsens the patient conditions and impairment, increasing neuronal loss and glial reaction, which in turn further decreases the chances of a positive outcome. The possibility of using hemostatic substances that also function as a scaffold, such as the fibrin sealant, reduces surgical time and improve postoperative recovery. To date, several studies have demonstrated that human blood derived fibrin sealant produces positive effects in different interventions, becoming an efficient alternative to suturing. To provide an alternative to homologous fibrin sealants, the Center for the Study of Venoms and Venomous Animals (CEVAP, Brazil) has proposed a new bioproduct composed of certified animal components, including a thrombin-like enzyme obtained from snake venom and bubaline fibrinogen. Thus, the present review brings up to date literature assessment on the use of fibrin sealant for nervous system repair and positions the new heterologous bioproduct from CEVAP as an alternative to the commercial counterparts. In this way, clinical and pre-clinical data are discussed in different topics, ranging from central nervous system to peripheral nervous system applications, specifying positive results as well as future enhancements that are necessary for improving the use of fibrin sealant therapy. 23 1 Sao Paulo Research Foundation (FAPESP) [2009/53846-9, 2010/00729-2, 2011/23377-7, 2011/02889-0, 2012/22750-9, 2012/02689-3, 2012/08101-8, 2012/13514-0, 2012/20456-6, 2013/23030-2, 2013/04409-0, 2014/06892-3, 2014/11405-4] National Council for Scientific and Technological Development (CNPq) [300553/2013-9, 563582/2010-3] Coordination for the Improvement of Higher Education Personnel (CAPES) through Edital Toxinologia CAPES [063/2010, 230.38.006285/2011-21] AUXPE Toxinologia [1219/2011] CNPq DTI [310395/2014-3] Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)